NASDAQ:VXRT - Vaxart Stock Price, News & Analysis

-0.02 (-3.02 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
Now: $0.6413
50-Day Range
MA: $0.68
52-Week Range
Now: $0.6413
Volume133,970 shs
Average Volume473,783 shs
Market Capitalization$10.12 million
P/E RatioN/A
Dividend YieldN/A
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI



Sales & Book Value

Annual Sales$4.16 million
Book Value$1.57 per share


Net Income$-18,000,000.00
Net Margins-244.38%


Market Cap$10.12 million
Next Earnings DateN/A
OptionableNot Optionable

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

How were Vaxart's earnings last quarter?

Vaxart Inc (NASDAQ:VXRT) issued its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.11. The biotechnology company earned $0.09 million during the quarter, compared to the consensus estimate of $1.10 million. Vaxart had a negative return on equity of 131.05% and a negative net margin of 244.38%. View Vaxart's Earnings History.

What price target have analysts set for VXRT?

2 brokers have issued 12 month price targets for Vaxart's shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Vaxart's stock price to reach $4.00 in the next year. This suggests a possible upside of 523.7% from the stock's current price. View Analyst Price Targets for Vaxart.

What is the consensus analysts' recommendation for Vaxart?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaxart.

Has Vaxart been receiving favorable news coverage?

Press coverage about VXRT stock has been trending negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Vaxart.

Are investors shorting Vaxart?

Vaxart saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 352,100 shares, an increase of 12.8% from the July 31st total of 312,200 shares. Based on an average daily volume of 138,800 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.9% of the company's shares are sold short. View Vaxart's Current Options Chain.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the folowing people:
  • Dr. Wouter W. Latour M.B.A., M.D., MBA, Pres, CEO, CFO & Director (Age 61)
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 51)
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 67)
  • Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 60)
  • Mr. Brant Biehn, Sr. VP of Commercial Operations

Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.69%) and Vanguard Group Inc. (0.57%). Company insiders that own Vaxart stock include Michael J Finney and Sean Tucker. View Institutional Ownership Trends for Vaxart.

Which institutional investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Vanguard Group Inc.. Company insiders that have bought Vaxart stock in the last two years include Michael J Finney and Sean Tucker. View Insider Buying and Selling for Vaxart.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $0.6413.

How big of a company is Vaxart?

Vaxart has a market capitalization of $10.12 million and generates $4.16 million in revenue each year. The biotechnology company earns $-18,000,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Vaxart employs 34 workers across the globe.View Additional Information About Vaxart.

What is Vaxart's official website?

The official website for Vaxart is

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]

MarketBeat Community Rating for Vaxart (NASDAQ VXRT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  444
MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote "Outperform" if you believe VXRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel